Our Reports
Automotive Reports Electronics & Semiconductor Telecom & IT Technology & IT Consumer Goods Healthcare Food & Beverages Chemical
Our Links
About Us Contact Us Press Release News Our Blogs

Int'l : +1(646) 600-5072 | query@kbvresearch.com

Europe Biodefense Market By Product (Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products), By Country, Industry Analysis and Forecast, 2020 - 2026

Published Date : 3-Feb-2021

Pages: 68

Formats: PDF

The Europe Biodefense Market would witness market growth of 5.4% CAGR during the forecast period (2020-2026). Bioterrorism refers to the utilization of biological agents that are damaging the mankind. Biodefense means the usage of medical steps in order to save mankind from bioterrorism, including interventions like drugs and vaccinations. Moreover, research and public health preparations have seen development to counter biological attacks.

Over the last few years, genetic engineering and biotechnology have seen massive technological advancements, which have offered innovative ways to address these deadly and naturally occurring viruses that can be re-designed to create additional harm. Also, there is the easy availability of these organisms, which makes biodefense a significant aspect for countries across the globe. To carry out bioterrorism, various biological agents have been used such as botulism, anthrax, and chemical & nuclear agents, causing severe destruction.

The biodefense market is still in the initial phase. The governments in emerging and developed countries are taking several initiatives that ensure the safety of the population. Various governments are proposing programs that include storing vaccines and biodefense machines used on account of a sudden bioterrorism attack.

Based on Product, the market is segmented into Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

Free Valuable Insights: Biodefense Market in Europe is expected to register a CAGR of 5.4% during the forecast period (2020-2026)

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Xoma Corporation, Altimmune, Inc., Emergent BioSolutions, Inc., Dynavax Technologies Corporation, SIGA Technologies, Inc., Elusys Therapeutics, Inc., Ichor Holdings, Ltd., Cleveland BioLabs, Inc., Bavarian Nordic A/S and Alnylam Pharmaceuticals, Inc.

Scope of the Study

Market Segments Covered in the Report:

By Product

  • Anthrax
  • Smallpox
  • Botulism
  • Radiation/nuclear
  • Other Products

By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Companies Profiled

  • IBM Corporation
  • SAP SE
  • Teradata Corporation
  • Microsoft Corporation
  • HCL Technologies Ltd. (HCL Enterprises)
  • Adobe, Inc.
  • Oracle Corporation
  • Infor, Inc. (Koch Industries)
  • SAS Institute, Inc.
  • North Plains Systems Corporation (Aclate, Inc.)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Biodefense Market, by Product
1.4.2 Europe Biodefense Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 Recent Industry Wide Strategic Developments
3.1.1 Partnerships, Collaborations and Agreements
3.1.2 Approvals
3.1.3 Acquisition and Mergers
3.2 Top Winning Strategies
3.2.1 Key Leading Strategies: Percentage Distribution (2016-2020)
3.2.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Jul – 2020, Jul) Leading Players

Chapter 4. Europe Biodefense Market by Product
4.1 Europe Anthrax Market by Country
4.2 Europe Smallpox Market by Country
4.3 Europe Botulism Market by Country
4.4 Europe Radiation/nuclear Market by Country
4.5 Europe Other Product Market by Country

Chapter 5. Europe Biodefense Market by Country
5.1 Germany Biodefense Market
5.1.1 Germany Biodefense Market by Product
5.2 UK Biodefense Market
5.2.1 UK Biodefense Market by Product
5.3 France Biodefense Market
5.3.1 France Biodefense Market by Product
5.4 Russia Biodefense Market
5.4.1 Russia Biodefense Market by Product
5.5 Spain Biodefense Market
5.5.1 Spain Biodefense Market by Product
5.6 Italy Biodefense Market
5.6.1 Italy Biodefense Market by Product
5.7 Rest of Europe Biodefense Market
5.7.1 Rest of Europe Biodefense Market by Product

Chapter 6. Company Profiles
6.1 Xoma Corporation
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expense
6.2 Altimmune, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Research & Development Expense
6.2.4 Recent strategies and developments:
6.2.4.1 Acquisition and Mergers:
6.2.4.2 Partnerships, Collaborations, and Agreements:
6.3 Emergent BioSolutions, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Research & Development Expense
6.3.4 Recent strategies and developments:
6.3.4.1 Acquisition and Mergers:
6.3.4.2 Partnerships, Collaborations, and Agreements:
6.4 Dynavax Technologies Corporation
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Research & Development Expense
6.5 SIGA Technologies, Inc.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Research & Development Expense
6.5.4 Recent strategies and developments:
6.5.4.1 Partnerships, Collaborations, and Agreements:
6.5.4.2 Approvals:
6.6 Elusys Therapeutics, Inc.
6.6.1 Company Overview
6.6.2 Recent strategies and developments:
6.6.2.1 Approvals:
6.7 Ichor Holdings, Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.7.5 Recent strategies and developments:
6.7.5.1 Partnerships, Collaborations, and Agreements:
6.8 Cleveland BioLabs, Inc.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Research & Development Expense
6.8.4 Recent strategies and developments:
6.8.4.1 Partnerships, Collaborations, and Agreements:
6.9 Bavarian Nordic A/S
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.9.5 Recent strategies and developments:
6.9.5.1 Partnerships, Collaborations, and Agreements:
6.9.5.2 Approvals:
6.10. Alnylam Pharmaceuticals, Inc.
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Research & Development Expense
TABLE 1 Europe Biodefense Market, 2016 - 2019, USD Million
TABLE 2 Europe Biodefense Market, 2020 - 2026, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Bio-defense Market
TABLE 4 Approvals– Bio-defense Market
TABLE 5 Acquisition and Mergers– Bio-defense Market
TABLE 6 Europe Biodefense Market by Product, 2016 - 2019, USD Million
TABLE 7 Europe Biodefense Market by Product, 2020 - 2026, USD Million
TABLE 8 Europe Anthrax Market by Country, 2016 - 2019, USD Million
TABLE 9 Europe Anthrax Market by Country, 2020 - 2026, USD Million
TABLE 10 Europe Smallpox Market by Country, 2016 - 2019, USD Million
TABLE 11 Europe Smallpox Market by Country, 2020 - 2026, USD Million
TABLE 12 Europe Botulism Market by Country, 2016 - 2019, USD Million
TABLE 13 Europe Botulism Market by Country, 2020 - 2026, USD Million
TABLE 14 Europe Radiation/nuclear Market by Country, 2016 - 2019, USD Million
TABLE 15 Europe Radiation/nuclear Market by Country, 2020 - 2026, USD Million
TABLE 16 Europe Other Product Market by Country, 2016 - 2019, USD Million
TABLE 17 Europe Other Product Market by Country, 2020 - 2026, USD Million
TABLE 18 Europe Biodefense Market by Country, 2016 - 2019, USD Million
TABLE 19 Europe Biodefense Market by Country, 2020 - 2026, USD Million
TABLE 20 Germany Biodefense Market, 2016 - 2019, USD Million
TABLE 21 Germany Biodefense Market, 2020 - 2026, USD Million
TABLE 22 Germany Biodefense Market by Product, 2016 - 2019, USD Million
TABLE 23 Germany Biodefense Market by Product, 2020 - 2026, USD Million
TABLE 24 UK Biodefense Market, 2016 - 2019, USD Million
TABLE 25 UK Biodefense Market, 2020 - 2026, USD Million
TABLE 26 UK Biodefense Market by Product, 2016 - 2019, USD Million
TABLE 27 UK Biodefense Market by Product, 2020 - 2026, USD Million
TABLE 28 France Biodefense Market, 2016 - 2019, USD Million
TABLE 29 France Biodefense Market, 2020 - 2026, USD Million
TABLE 30 France Biodefense Market by Product, 2016 - 2019, USD Million
TABLE 31 France Biodefense Market by Product, 2020 - 2026, USD Million
TABLE 32 Russia Biodefense Market, 2016 - 2019, USD Million
TABLE 33 Russia Biodefense Market, 2020 - 2026, USD Million
TABLE 34 Russia Biodefense Market by Product, 2016 - 2019, USD Million
TABLE 35 Russia Biodefense Market by Product, 2020 - 2026, USD Million
TABLE 36 Spain Biodefense Market, 2016 - 2019, USD Million
TABLE 37 Spain Biodefense Market, 2020 - 2026, USD Million
TABLE 38 Spain Biodefense Market by Product, 2016 - 2019, USD Million
TABLE 39 Spain Biodefense Market by Product, 2020 - 2026, USD Million
TABLE 40 Italy Biodefense Market, 2016 - 2019, USD Million
TABLE 41 Italy Biodefense Market, 2020 - 2026, USD Million
TABLE 42 Italy Biodefense Market by Product, 2016 - 2019, USD Million
TABLE 43 Italy Biodefense Market by Product, 2020 - 2026, USD Million
TABLE 44 Rest of Europe Biodefense Market, 2016 - 2019, USD Million
TABLE 45 Rest of Europe Biodefense Market, 2020 - 2026, USD Million
TABLE 46 Rest of Europe Biodefense Market by Product, 2016 - 2019, USD Million
TABLE 47 Rest of Europe Biodefense Market by Product, 2020 - 2026, USD Million
TABLE 48 Key Information –Xoma Corporation
TABLE 49 Key Information – Altimmune, Inc.
TABLE 50 Key Information – Emergent BioSolutions, Inc.
TABLE 51 Key Information – Dynavax Technologies Corporation
TABLE 52 Key Information – SIGA Technologies, Inc.
TABLE 53 key information – Elusys Therapeutics, Inc.
TABLE 54 key Information – Ichor Holdings, Ltd.
TABLE 55 Key Information – Cleveland BioLabs, Inc.
TABLE 56 key information – Bavarian Nordic A/S
TABLE 57 Key Information – Alnylam Pharmaceuticals, Inc.

List of Figures
FIG 1 Methodology for the research
FIG 2 Key Leading Strategies: Percentage Distribution (2016-2020)
FIG 3 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Jul – 2020, Jul) Leading Players
FIG 4 Recent strategies and developments: Altimmune, Inc.
FIG 5 Recent strategies and developments: Emergent BioSolutions, Inc.

Purchase Full Report of
Europe Biodefense Market

Buy Now

Avail up to 60% discount on subscription plans on

SUBSCRIPTION MODEL